Journal
CLINICAL MICROBIOLOGY REVIEWS
Volume 15, Issue 2, Pages 194-+Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/CMR.15.2.194-222.2002
Keywords
-
Categories
Funding
- NEI NIH HHS [F32 EY006805, EY 06805] Funding Source: Medline
- NHLBI NIH HHS [R01 HL058398, HL 58398] Funding Source: Medline
- NIAID NIH HHS [R01 AI048917, AI 48917] Funding Source: Medline
Ask authors/readers for more resources
While originally characterized as a collection of related Syndromes, cystic fibrosis (CF) is now recognized as a single disease whose diverse synptoms stern from the wide tissue distribution of the gene product that is defective in CF, the ion channel and regulator, cystic fibrosis transmembrane conductance regulator (CFTR). Defective CFTR protein impacts the function of the pancreas and alters the consistency of mucosal secretions. The latter of these effects probably plays an important role in the defective resistance of CF patients to many pathogens. As the modalities of CF research have changed over the decades from empirical histological studies to include biophysical measurements of CFTR function, the clinical management of this disease has similarly evolved to effectively address the ever-changing spectrum of CF-related infectious diseases. These factors have led to the successful management of many CF-related infections with the notable exception of chronic lung infection with the grain-negative bacterium Pseudomonas aeruginosa. The virulence of P. aeruginosa sterns from multiple bacterial attributes, including antibiotic resistance, the ability to utilize quorum-sensing signals to form biofilms, the destructive potential of a multitude of its microbial toxins, and the ability to acquire a mucoid phenotype, which renders this microbe resistant to both the innate and acquired immunologic defenses of the host.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available